Atherosclerosis is an area of vast opportunity for pharmaceutical companies. This disease is the leading cause of morbidity and mortality in Western societies and claims more lives each year than all forms of cancer combined. Coronary artery disease (CAD) is the most common and serious consequence of this disease. Up to 50% of all deaths in the seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) are attributable to CAD.

(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION )

Decision Resources, Inc., announces the publication of Atherosclerosis, a multiclient study that evaluates the commercial prospects of current and emerging drugs to treat this disease. Among the developments discussed in this study are recent trial data showing that angiotensin-converting enzyme (ACE) inhibitors may have a key role in CAD prevention. The Heart Outcomes Prevention Evaluation (HOPE) study found substantial reductions in morbidity and mortality among patients treated with the ACE inhibitor ramipril (Hoechst Marion Roussel's Altace).

In 1998, we estimate that the total sales of drugs for the treatment of atherosclerosis (cholesterol-lowering therapies, antiplatelet agents, and ACE inhibitors) in the seven major pharmaceutical markets totaled slightly more than $9 billion. By 2008, the end of our forecast period, we expect this market to exceed $13.7 billion, due to the aging of the population, increased diagnosis, and the potential introduction of new classes of drugs.

Atherosclerosis is part of Cardium, a multiclient service that evaluates the commercial potential of cardiac drugs in research and development.

Contact: Frank Sama, 781.487.3753 (telephone), 781.487.5750 (fax), or sama@dresources.com (e-mail). In Europe, contact Ms. Francoise Bidart, +32.2.351.1079 (telephone), +32.2.351.2347 (fax), or fbidart@decisionresources.be (e-mail). In Japan, contact Ms. Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or makiko@bl.mmtr.or.jp (e-mail). http://www.dresources.com

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing industry trends in the international health care and pharmaceutical industries.

NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION

AP Archive: http://photoarchive.ap.org/

PRN Photo Desk, 888-776-6555 or 201-369-3467

SOURCE: Decision Resources, Inc.

Contact: Frank Sama of Decision Resources, Inc, 781-487-3753,
sama@dresources.com

Novel Agents Are Transforming the Rheumatoid Arthritis Market -- A Decision Resources Study Evaluates Their Therapeutic and Commercial Potential

View Now